Tizanidine Hydrochloride Capsule
Product Images NDC 60760-892

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Tizanidine Hydrochloride (NDC 60760-892). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by St. Mary's Medical Park Pharmacy, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

892-30 (Tizanidine 60760 892 30)

Label for Tizanidine Hydrochloride Capsules 6 mg, an oral prescription drug. The label indicates a quantity of 30 capsules per package. The product is manufactured by Ingenus Pharmaceuticals, LLC, Orlando, FL, and packaged by St. Mary's Medical Park Pharmacy, Oro Valley, AZ. The label includes storage instructions to keep at controlled room temperature 15°-30°C (59°-86°F) and states 'Use as directed' and 'Rx only.' Various data fields such as lot number and expiration date are shown as placeholders.*

FDA Label Image

Tizanidine Structure (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 01)

Chemical structure diagram of tizanidine hydrochloride, illustrating its molecular framework including chlorine, nitrogen, sulfur atoms, and associated bonds as part of the compound's chemical identity.*

FDA Label Image

Figure 1 (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 02)

Pharmacokinetic line graph depicting plasma tizanidine concentration (ng/mL) over 24 hours post-dosing. Four dosing conditions are compared: 2 x 4 mg tizanidine tablets with food, without food, and 2 x 4 mg tizanidine capsules with and without food. The concentration peaks within a few hours and declines thereafter.*

FDA Label Image

Figure 2 (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 03)

A line graph showing improvement in Ashworth Score over time (up to 6 hours post-dose) comparing 16 mg tizanidine, 8 mg tizanidine, and placebo. The graph displays mean improvement values with error bars for each time point, indicating greater improvement with 16 mg and 8 mg tizanidine doses compared to placebo.*

FDA Label Image

Figure 3 (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 04)

A line chart depicting improvement in Ashworth Score over three time points: End of Titration (Week 3), End of Maintenance (Week 7), and Endpoint (Last Observation). It compares tizanidine (mean dose 28.8 mg) and placebo groups, showing greater improvement (negative scores) with tizanidine across all time points with error bars indicating variability.*

FDA Label Image

Image (Fe05ad15 Db11 4d9e 9fb8 721cec4633d9 143 1)

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.